問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

National Taiwan University Hospital (在職)

Division of Hematology & Oncology

更新時間：2024-06-12

陳聰智Chen, Tsung -Chih
  • Principal Investigator
  • Clinical Trial Experience (year)

  • tjchen9477@gmail.com

Recruiting Trial

31Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳聰智

List

47Cases

2020-01-11 - 2027-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2020-04-01 - 2032-06-30

Others

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2021-02-19 - 2025-12-31

Phase I

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Not yet recruiting5Sites

2021-08-01 - 2021-09-27

Phase I/II

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Terminated2Sites

2018-12-06 - 2026-03-31

Phase II

Active
A Phase II, Open-label Study of CVM-1118 Administered Orally to Patients with Advanced Neuroendocrine Tumors

  • Condition/Disease

    Neuroendocrine Tumors Pancreatic Neuroendocrine Tumor Gastro-enteropancreatic Neuroendocrine Tumor Lung Neuroendocrine Neoplasm Neuroendocrine Carcinoma

  • Test Drug

    CVM-1118 Capsules

Participate Sites
8Sites

Recruiting3Sites

Terminated4Sites

陳明晃
Taipei Veterans General Hospital

Division of Hematology & Oncology

白禮源
China Medical University Hospital-Taipei

未分科

2017-11-01 - 2020-03-19

Phase II/III

Completed
A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC)and Autologous Stem-Cell Transplantation (ASCT) – B-MIND

  • Condition/Disease

    Diffuse Large B-cell Lymphoma

  • Test Drug

    MOR00208

Participate Sites
11Sites

Not yet recruiting7Sites

Terminated3Sites

白禮源
China Medical University Hospital-Taipei

未分科

2022-01-14 - 2027-05-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting4Sites

2022-04-01 - 2029-10-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Not yet recruiting3Sites

Recruiting1Sites

2022-09-01 - 2028-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2026-06-01 - 2032-11-30

Phase II/III

Active
A Randomized Phase 2/3 Study Evaluating the Safety and Efficacy of Pivekimab Sunirine (PVEK) in Combination with Venetoclax and Azacitidine in Adult Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible to Receive Intensive Chemotherapy

  • Condition/Disease

    Acute Myeloid Leukemia

  • Test Drug

    Azacitidine Pivekimab sunirine (IMGN632) Venetoclax Venetoclax Venetoclax

Participate Sites
5Sites

Not yet recruiting5Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB